Bayer Regeneron Eye Drug Meets Study Goal
By wchung | 10 Mar, 2026
Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG said Thursday their developing VEGF Trap-Eye drug met key vision improvement goals in a midstage study.
The drug is aimed at improving vision in patients with diabetic macular edema. The condition is a disease of the retina that affects individuals with diabetes and can lead to blindness.
The study, which took place over 24 weeks, compared VEGF Trap-Eye with laser therapy.
The companies also said VEGF Trap-Eye was well tolerated, and there were no drug-related serious adverse events.
Shares of Regeneron, which is based in Tarrytown, N.Y., closed at $30.46 Wednesday. Bayer HealthCare AG is based in Germany.
2/18/2010 8:18 AM NEW YORK (AP)
Articles
- Daughter of Alberto Fujimori Leads Peru Presidential Race
- How Ben Played Don to Paint the Fence
- Air Optics Revamps Fiber Optics for Faster, Cooler Data Transmission
- China Tech Hubs Fund Super-Efficient One-Person Companies Using OpenClaw AI Agent
- US, EU and 9 Nations Sought Ukraine Help Downing Iranian Drones
- Imperial Valley Lithium Producer to go Public via $4.7 Billion SPAC Deal
- Nvidia-Backed Data-Center Firm Nscale Valued at $14.6 Billion in Latest Funding Round
- Nexperia's China Subsidiary Produces Own Auto Chips Free of Dutch Parent
- Chinese Battery Makers Soar with Global EV Adoption
- Mamdani Targeted at Gracie Mansion with Dud Homemade Bomb